Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1876
Euronet Worldwide
EEFT
$2.78B
| $6.24M | ﹤0.01% |
62,862
+950
| +2% | +$96.1K |
|
1877
Ashland
ASH
$3.28B
| $6.23M | ﹤0.01% |
71,689
+54,745
| +323% | +$4.9M |
|
1878
Standard BioTools
LAB
$307M
| $6.23M | ﹤0.01% |
3,228,360
+377,195
| +13% | +$739K |
|
1879
CALL
Arbor Realty Trust
ABR
$965M
| $6.22M | ﹤0.01% |
+400,000
| New | +$5.56M |
|
1880
National Fuel Gas
NFG
$7.5B
| $6.22M | ﹤0.01% |
102,672
+72,802
| +244% | +$4.26M |
|
|
BRSL
1881
Brightstar Lottery PLC
BRSL
$2.08B
| $6.21M | ﹤0.01% |
291,626
+96,019
| +49% | +$2.06M |
|
1882
Immunovant
IMVT
$8.11B
| $6.21M | ﹤0.01% |
217,812
+119,372
| +121% | +$3.52M |
|
1883
Sensient Technologies
SXT
$5.54B
| $6.2M | ﹤0.01% |
77,260
+58,386
| +309% | +$4.43M |
|
1884
PTC Therapeutics
PTCT
$5.78B
| $6.2M | ﹤0.01% |
167,012
+102,138
| +157% | +$3.42M |
|
1885
Affirm
AFRM
$26.3B
| $6.19M | ﹤0.01% |
151,652
+71,118
| +88% | +$2.36M |
|
1886
Donaldson
DCI
$11.3B
| $6.17M | ﹤0.01% |
83,738
+13,568
| +19% | +$981K |
|
1887
Blue Bird Corp
BLBD
$2.43B
| $6.17M | ﹤0.01% |
128,658
+116,707
| +977% | +$5.77M |
|
1888
Neogen
NEOG
$2.49B
| $6.17M | ﹤0.01% |
366,753
+207,160
| +130% | +$3.41M |
|
|
PRMW
1889
DELISTED
Primo Water Corporation
PRMW
| $6.16M | ﹤0.01% |
244,054
+166,579
| +215% | +$3.72M |
|
1890
Burford Capital
BUR
$935M
| $6.15M | ﹤0.01% |
463,979
-86,320
| -16% | -$1.15M |
|
1891
PUT
Bristol-Myers Squibb
BMY
$130B
| $6.15M | ﹤0.01% |
+118,800
| New | +$5.57M |
|
1892
Evercore
EVR
$12.3B
| $6.14M | ﹤0.01% |
24,251
+798
| +3% | +$190K |
|
1893
Patrick Industries
PATK
$2.9B
| $6.14M | ﹤0.01% |
64,692
+37,266
| +136% | +$3.13M |
|
1894
WSFS Financial
WSFS
$4.23B
| $6.14M | ﹤0.01% |
120,397
+63,284
| +111% | +$3.28M |
|
1895
Archrock
AROC
$5.95B
| $6.12M | ﹤0.01% |
302,610
+167,648
| +124% | +$3.39M |
|
1896
PUT
Cinemark Holdings
CNK
$4.38B
| $6.12M | ﹤0.01% |
+220,000
| New | +$5.59M |
|
1897
PUT
On Holding
ONON
$12.7B
| $6.11M | ﹤0.01% |
+121,900
| New | +$5.23M |
|
1898
Pacira BioSciences
PCRX
$991M
| $6.1M | ﹤0.01% |
405,477
-15,778
| -4% | -$270K |
|
1899
CRISPR Therapeutics
CRSP
$5.07B
| $6.1M | ﹤0.01% |
129,848
+64,228
| +98% | +$3.26M |
|
1900
PVH
PVH
$4.01B
| $6.1M | ﹤0.01% |
60,495
+25,174
| +71% | +$2.5M |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.